Rezolute, Inc. reported Q2 fiscal 2026 financial results with net loss of $22.8 million and cash position of $132.9 million as of December 31, 2025. The Phase 3 sunRIZE study for ersodetug in congenital HI missed primary and key secondary endpoints, though all participants continued into open-label extension; upLIFT tumor HI study enrollment is ongoing with topline results expected H2 2026.
Key takeaways
sunRIZE Phase 3 missed primary/secondary endpoints due to study effect but showed CGM hypoglycemia reduction significant at Week 16
All 59 sunRIZE participants continued to open-label extension; some children on ersodetug monotherapy
upLIFT Phase 3 tumor HI enrollment underway, topline H2 2026; EAP data: 75% of 9 patients discontinued IV dextrose/TPN